|
1
|
Zhang H, Zuh W, Biskup E, Yang W, Yang Z,
Wang H, Qiu X, Zhang C and Hu G and Hu G: Incidence, risk factors
and prognostic characteristics of bone metastases and
skeletal-related events (SREs) in breast cancer patients: A
systematic review of the real world data. J Bone Oncol. 11:38–50.
2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Coleman RE: Clinical features of
metastatic bone disease and risk of skeletal morbidity. Clin Cancer
Res. 12:6243S–6249S. 2006.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Gambardella C, Mongardini FM, Paolicelli
M, Bentivoglio D, Cozzolino G, Ruggiero R, Pizza A, Tolone S, Del
Genio G, Parisi S, et al: Role of inflammatory biomarkers (NLR,
LMR, PLR) in the prognostication of malignancy in indeterminate
thyroid nodules. Int J Mol Sci. 24(6466)2023.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Tumer AA and Rashid FA: The relationship
between circulating irisin and oxidative stress in gastric and
colorectal cancer patients. Asian Pac J Cancer Prev. 23:2649–2654.
2022.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Wang J, Loberg R and Taichman RS: The
pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis.
Cancer Metastasis Rev. 25:573–587. 2006.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Sasaki K, Natsugoe S, Ishigami S,
Matsumoto M, Okumura H, Setoyama T, Uchikado Y, Kita Y, Tamotsu K,
Hanazono K, et al: Expression of CXCL12 and its receptor CXCR4 in
esophageal squamous cell carcinoma. Oncol Rep. 21:65–71.
2009.PubMed/NCBI
|
|
7
|
Machelon V, Gaudin F, Camilleri-Broët S,
Nasreddine S, Bouchet-Delbos L, Pujade-Lauraine E, Alexandre J,
Gladieff L, Arenzana-Seisdedos F, Emilie D, et al: CXCL12
expression by healthy and malignant ovarian epithelial cells. BMC
Cancer. 11(97)2011.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Schrader AJ, Lechner O, Templin M, Dittmar
KE, Machtens S, Mengel M, Probst-Kepper M, Franzke A, Wollensak T,
Gatzlaff P, et al: CXCR4/CXCL12 expression and signalling in kidney
cancer. Br J Cancer. 86:1250–1256. 2002.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Potić Floranović M, Ristić Petrović A,
Veličković F and Janković Veličković L: Expression and prognostic
value of CXCL12/CXCR4/CXCR7 axis in clear cell renal cell
carcinoma. Clin Exp Nephrol. 25:1057–1069. 2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Mousavi A, Hashemzadeh S, Bahrami T,
Estiar MA, Feizi MAH, Pouladi N, Rostamizadeh L and Sakhinia E:
Expression patterns of CXCL12 and its receptor in colorectal
carcinoma. Clin Lab. 64:871–876. 2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Sun Y, Mao X, Fan C, Liu C, Guo A, Guan S,
Jin Q, Li B, Yao F and Jin F: CXCL12-CXCR4 axis promotes the
natural selection of breast cancer cell metastasis. Tumour Biol.
35:7765–7773. 2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Teicher BA and Fricker SP: CXCL12
(SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 16:2927–2931.
2010.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Łukaszewicz-Zając M, Mroczko B, Kozłowski
M and Szmitkowski M: The serum concentrations of chemokine CXCL12
and its specific receptor CXCR4 in patients with esophageal cancer.
Dis Markers. 2016(7963895)2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Dabrowska E, Przylipiak A, Zajkowska M,
Piskor BM, Sidorkiewicz I, Szmitkowski M and Lawicki S: Possible
diagnostic application of CXCL12 and CXCR4 as tumor markers in
breast cancer patients. Anticancer Res. 40:3221–3229.
2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Fejzić H, Mujagić S, Azabagić S and Burina
M: Tumor marker CA 15-3 in breast cancer patients. Acta Med Acad.
44:39–46. 2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Zhang Y, Zhao J, Wang Y, Cai W, Zhang X,
Li K, Liu W, Zhao Y and Kang H: Changes of tumor markers in
patients with breast cancer during postoperative adjuvant
chemotherapy. Dis Markers. 2022(7739777)2022.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Chu WG and Ryu DW: Clinical significance
of serum CA15-3 as a prognostic parameter during follow-up periods
in patients with breast cancer. Ann Surg Treat Res. 90:57–63.
2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Yerushalmi R, Tyldesley S, Kennecke H,
Speers C, Woods R, Knight B and Gelmon KA: Tumor markers in
metastatic breast cancer subtypes: Frequency of elevation and
correlation with outcome. Ann Oncol. 23:338–345. 2012.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Sturgeon CM, Lai CL and Duffy MJ: Serum
tumour markers: How to order and interpret them. BMJ.
339(b3527)2009.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Prevarskaya N, Ouadid-Ahidouch H, Skryma R
and Shuba Y: Remodelling of Ca2+ transport in cancer: How it
contributes to cancer hallmarks? Philos Trans R Soc Lond B Biol
Sci. 369(20130097)2014.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Monteith GR, Davis FM and Roberts-Thomson
SJ: Calcium channels and pumps in cancer: Changes and consequences.
J Biol Chem. 287:31666–31673. 2012.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Monteith GR, McAndrew D, Faddy HM and
Roberts-Thomson SJ: Calcium and cancer: Targeting Ca2+ transport.
Nat Rev Cancer. 7:519–530. 2007.PubMed/NCBI View
Article : Google Scholar
|
|
23
|
Schwartz GG: Prostate cancer, serum
parathyroid hormone, and the progression of skeletal metastases.
Cancer Epidemiol Biomarkers Prev. 17:478–483. 2008.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Yang Z, Yue Z, Ma X and Xu Z: Calcium
homeostasis: A potential vicious cycle of bone metastasis in breast
cancers. Front Oncol. 10(293)2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Almuradova E and Cicin I: Cancer-related
hypercalcemia and potential treatments. Front Endocrinol.
14(1039490)2023.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Huang P, Lan M, Peng AF, Yu QF, Chen WZ,
Liu ZL, Liu JM and Huang SH: Serum calcium, alkaline phosphotase
and hemoglobin as risk factors for bone metastases in bladder
cancer. PLoS One. 12(e0183835)2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Potts JT and Gardella TJ: Chapter
6-Parathyroid Hormone and Calcium Homeostasis, in Pediatric Bone.
(Second Edition), Glorieux FH, Pettifor JM, and Jüppner H: Academic
Press, San Diego. pp109-140, 2012.
|
|
28
|
Brown HK, Allocca G, Ottewell PD, Wang N,
Brown NJ, Croucher PI, Eaton CL and Holen I: Parathyroid hormone
(PTH) increases skeletal tumour growth and alters tumour
distribution in an in vivo model of breast cancer. Int J Mol Sci.
19(2920)2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Zissimopoulos A, Stellos K, Matthaios D,
Petrakis G, Parmenopoulou V, Babatsikou F, Matthaiou E,
Theodosiadou E, Hountis P and Koutis C: Type I collagen biomarkers
in the diagnosis of bone metastases in breast cancer, lung cancer,
urinary bladder cancer and prostate cancer. Comparison to CEA, CA
15-3, PSA and bone scintigraphy. J BUON. 14:463–472.
2009.PubMed/NCBI
|
|
30
|
Tähtelä R and Thölix E: Serum
concentrations of type I collagen carboxyterminal telopeptide
(ICTP) and type I procollagen carboxy-and aminoterminal propeptides
(PICP, PINP) as biomarkers of metastatic bone disease in breast
cancer. Anticancer Res. 16:2289–2293. 1996.PubMed/NCBI
|
|
31
|
Wang W, Xu X, Tian B, Wang Y, Du L, Sun T,
Shi Y, Zhao X and Jing J: The diagnostic value of serum tumor
biomarkers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast
cancer. Clin Chim Acta. 470:51–55. 2017.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Manders K, van de Poll-Franse LV, Creemers
GJ, Vreugdenhil G, van der Sangen MJ, Nieuwenhuijzen GA, Roumen RM
and Voogd AC: Clinical management of women with metastatic breast
cancer: A descriptive study according to age group. BMC Cancer.
6(179)2006.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Coleman RE, Smith P and Rubens RD:
Clinical course and prognostic factors following bone recurrence
from breast cancer. Br J Cancer. 77:336–340. 1998.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Motyka J, Gacuta E, Kicman A, Kulesza M,
Malinowski P and Ławicki S: CXCL12 and CXCR4 as potential early
biomarkers for luminal A and luminal B subtypes of breast cancer.
Cancer Manag Res. 15:573–589. 2023.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Neesanun S and Sriuranpong V: Association
of plasma CXCL12 level and bone metastasis in advance stage
non-small cell lung cancer patients in King Chulalongkorn Memorial
Hospital. J Clin Oncol. 33 (15_suppl)(e19099)2015.
|
|
36
|
Turanli S and Cetin A: Prognostic role of
serum cancer antigen 15-3 in breast cancer patients with isolated
bone metastases. Biomarkers. 15:418–423. 2010.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Cao R and Wang LP: Serological diagnosis
of liver metastasis in patients with breast cancer. Cancer Biol
Med. 9:57–62. 2012.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Chen WZ, Shen JF, Zhou Y, Chen XY, Liu JM
and Liu ZL: Clinical characteristics and risk factors for
developing bone metastases in patients with breast cancer. Sci Rep.
7(11325)2017.PubMed/NCBI View Article : Google Scholar
|
